The potential Role of Antidepressant Medications in DNA Oxidation of Depression Disorder Cases

Year : 2025 | Volume : | : | Page : –
By
vector

Zainab Mahdi Jasim Al-Saygh,

  1. Assistant Lecturer, Department of Biology, Faculty of Education for Girls, University of Kufa, , Iraq

Abstract

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_149193’);});Edit Abstract & Keyword

Oxidative stress and DNA oxidation is a main target of different medications side effect, the current work aims to evaluate the potential role of anti-depressed medications in DNA oxidation in depression disorder cases, reactive oxygen species (ROS), total antioxidant (TAO) and 8-oxo deoxyguanine (8-oxo-dG) were detected in depressed disorder cases that treated with different medications included clomipramine,  tryptizol, fluxetin, olanzapine, tryptizol with fluxetin, tryptizol with olanzapine and other types of medication. The results found significant differences in ROS and TAO (p0.000), non-significant changes in 8-oxo-dG (p 0.649). In addition to non-sig in age (p 0.081) and sig changes in BMI (p 0.035) between cases and control groups. The ROS levels in sub groups showed significant changes (p 0.016), the cases treated with tryptizol and olanzapine have high level of ROS (160.34±0.09), other types of medication have high level of ROS also (140±7.96), then the cases tryptizol and fluxetin have (137.7±53.35). The TAO have significant differences (p 0.000) among study sub groups clomipramine have high level of TAO (13.13±2.0), tryptizol (10.3±1.54), tryptizol with olanzapine have low level of TAO (8.21±0.09) and other types have (8.13±1.78), the 8-oxo-dG showed  significant differences (p 0.01). the high level of 8-oxo-dG was observed in others medications (56.82±3.92), then tryptizol with fluxetin (53.64±0.09), low level of oxidations were seen in clomipramine and olanzapine (14±7.9, 14.6±5.03). From present outputs we can concluded the clomipramine and olanzapine have antioxidant activity and low effect in DNA oxidation.

Keywords: potential role, anti-depressed medications, DNA oxidation , ROS, TAO, depression disorder cases

How to cite this article:
Zainab Mahdi Jasim Al-Saygh. The potential Role of Antidepressant Medications in DNA Oxidation of Depression Disorder Cases. Research & Reviews : A Journal of Life Sciences. 2025; ():-.
How to cite this URL:
Zainab Mahdi Jasim Al-Saygh. The potential Role of Antidepressant Medications in DNA Oxidation of Depression Disorder Cases. Research & Reviews : A Journal of Life Sciences. 2025; ():-. Available from: https://journals.stmjournals.com/rrjols/article=2025/view=0

document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_149193’);});Edit

References

  1.  Cipriani A, Zhou X, Del Giovane C, Hetrick SE, Qin B, Whittington C, Coghill D, Zhang Y, Hazell P, Leucht S, Cuijpers P. Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. The Lancet. 2016 Aug 27;388(10047):881-90.
  2. Wang L, Wang R, Liu L, Qiao D, Baldwin DS, Hou R. Effects of SSRIs on peripheral inflammatory markers in patients with major depressive disorder: a systematic review and meta-analysis. Brain, behavior, and immunity. 2019 Jul 1;79:24-38.
  3. Østergaard L, Jørgensen MB, Knudsen GM. Low on energy? An energy supply-demand perspective on stress and depression. Neuroscience & Biobehavioral Reviews. 2018 Nov 1;94:248-70.
  4.  Kraus C, Castrén E, Kasper S, Lanzenberger R. Serotonin and neuroplasticity–links between molecular, functional and structural pathophysiology in depression. Neuroscience & Biobehavioral Reviews. 2017 Jun 1;77:317-26.
  5.  Pilar-Cuéllar F, Vidal R, Díaz A, Castro E, dos Anjos S, Pascual-Brazo J, Linge R, Vargas V, Blanco H, Martínez-Villayandre B, Pazos Á. Neural plasticity and proliferation in the generation of antidepressant effects: hippocampal implication. Neural plasticity. 2013;2013(1):537265.
  6. Fakouri NB, Hou Y, Demarest TG, Christiansen LS, Okur MN, Mohanty JG, Croteau DL, Bohr   VA. Toward understanding genomic instability, mitochondrial dysfunction and aging. The FEBS journal. 2019 Mar;286(6):1058-73.
  7.  Schumacher B, Pothof J, Vijg J, Hoeijmakers JH. The central role of DNA damage in the ageing     process. Nature. 2021 Apr 29;592(7856):695-703.
  8. Nunomura A, Lee HG, Zhu X, Perry G. Consequences of RNA oxidation on protein synthesis rate and fidelity: implications for the pathophysiology of neuropsychiatric disorders. Biochemical Society Transactions. 2017 Oct 15;45(5):1053-66.
  9. Castellani RJ, Nunomura A, Rolston RK, Moreira PI, Takeda A, Perry G, Smith MA. Sublethal RNA oxidation as a mechanism for neurodegenerative disease. International journal of molecular sciences. 2008 May 20;9(5):789-806.
  10. Blackburn EH, Greider CW, Szostak JW. Telomeres and telomerase: the path from maize, Tetrahymena and yeast to human cancer and aging. Nature medicine. 2006 Oct 1;12(10):1133-8.
  11. Pousa PA, Souza RM, Melo PH, Correa BH, Mendonça TS, Simões-e-Silva AC, Miranda DM. Telomere shortening and psychiatric disorders: a systematic review. Cells. 2021 Jun 7;10(6):1423.
  12. Leone M, Kuja-Halkola R, Leval A, D’Onofrio BM, Larsson H, Lichtenstein P, Bergen SE. Association of youth depression with subsequent somatic diseases and premature death. JAMA psychiatry. 2021 Mar 1;78(3):302-10.
  13. Archer G, Kuh D, Hotopf M, Stafford M, Richards M. Association between lifetime affective symptoms and premature mortality. JAMA psychiatry. 2020 Aug 1;77(8):806-13.
  14. Copeland WE, Keen R, Tong G, Shanahan L. Negative life events and emotional symptoms from ages 2 to 30 years. JAMA network open. 2024 Aug 1;7(8):e2429448-.
  15. Jimenez-Fernandez S, Gurpegui M, Diaz-Atienza F, Pérez-Costillas L, Gerstenberg M, Correll CU. Oxidative stress and antioxidant parameters in patients with major depressive disorder compared to healthy controls before and after antidepressant treatment: results from a meta-analysis. The Journal of clinical psychiatry. 2015 Dec 23;76(12):13705.
  16.  Cumurcu BE, Ozyurt H, Etikan I, Demir S, Karlidag R. Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry and clinical neurosciences. 2009 Oct;63(5):639-45.
  17. Gerö D, Szoleczky P, Suzuki K, Módis K, Oláh G, Coletta C, Szabo C. Cell-based screening identifies paroxetine as an inhibitor of diabetic endothelial dysfunction. Diabetes. 2013 Mar 1;62(3):953-64.
  18.  Lopez-Vilchez I, Diaz-Ricart M, Navarro V, Torramade S, Zamorano-Leon J, Lopez-Farre A, Galan AM, Gasto C, Escolar G. Endothelial damage in major depression patients is modulated by SSRI treatment, as demonstrated by circulating biomarkers and an in vitro cell model. Translational psychiatry. 2016 Sep;6(9):e886-.
  19. Tutakhail A, Nazari QA, Khabil S, Gardier A, Coudore F. Muscular and mitochondrial effects of long-term fluoxetine treatment in mice, combined with physical endurance exercise on treadmill. Life sciences. 2019 Sep 1;232:116508.
  20.  Palta P, Samuel LJ, Miller III ER, Szanton SL. Depression and oxidative stress: results from a meta-analysis of observational studies. Psychosomatic medicine. 2014 Jan 1;76(1):12-9.
  21. Ahmadimanesh M, Abbaszadegan MR, Morshedi Rad D, Moallem SA, Mohammadpour AH, Ghahremani MH, Farid Hosseini F, Behdani F, Akhondpour Manteghi A, Jowsey P, Shabani Behbahani F. Effects of selective serotonin reuptake inhibitors on DNA damage in patients with depression. Journal of Psychopharmacology. 2019 Nov;33(11):1364-76.
  22.  Black CN, Bot M, Scheffer PG, Penninx BW. Oxidative stress in major depressive and anxiety disorders, and the association with antidepressant use; results from a large adult cohort. Psychological medicine. 2017 Apr;47(5):936-48.
  23. [23] Köhler-Forsberg K, Jorgensen A, Dam VH, Stenbæk DS, Fisher PM, Ip CT, Ganz M, Poulsen HE, Giraldi A, Ozenne B, Jørgensen MB. Predicting treatment outcome in major depressive disorder using serotonin 4 receptor PET brain imaging, functional MRI, cognitive-, EEG-based, and peripheral biomarkers: a neuropharm open label clinical trial protocol. Frontiers in psychiatry. 2020 Jul 23;11:641.
  24.  Kathem SH, Al-Jumail AA, Noor-Aldeen M, Najah N, Ali Khalid D. Measuring depression and anxiety prevalence among Iraqi healthcare college students using hospital anxiety and depression scale. Pharmacy Practice (Granada). 2021 Jun;19(2).
  25. Tripathi R, Alqahtani SS, Meraya AM, Makeen HA, Tripathi P, Pancholi SS. Evaluation of depression, anxiety, and stress among university healthcare students. Journal of Applied Pharmaceutical Science. 2022 Oct 4;12(10):078-87.
  26.  Al-Hamzawi AO, Bruffaerts R, Bromet EJ, AlKhafaji AM, Kessler RC. The epidemiology of major depressive episode in the Iraqi general population. PloS one. 2015 Jul 31;10(7):e0131937.
  27.  Jawad MA, Al-Terehi MN, Enad HA, Kareem TJ, Lazim AI. Estimation the Oxidative Stress State in Depression Disorders Patients. Clinical Schizophrenia & Related Psychoses. 2021 Oct 3;15.
  28.  Al-Terehi MN, Kadhim AJ, Mohsen IH, Alsaffar MF, Atiyah S, Hasan SY, Hamad DA, Bustani GS, Abdullah SA, Ramadhan RS. Association of 8-Oxo-2′-Deoxyguanosine, hOGG1 Ser326Cys Gene Polymorphism with Reactive Oxygen Species in Depression Patients. Clinical Schizophrenia & Related Psychoses. 2021 Oct 3;15.
  29.  Tsuboi H, Tatsumi A, Yamamoto K, Kobayashi F, Shimoi K, Kinae N. Possible connections among job stress, depressive symptoms, lipid modulation and antioxidants. Journal of affective disorders. 2006 Mar 1;91(1):63-70.
  30.  Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. International clinical psychopharmacology. 2004 Mar 1;19(2):89-95.
  31. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutrition, metabolism and cardiovascular diseases. 2005 Aug 1;15(4):316-28.
  32. Vieira EL, Mendes-Silva AP, Ferreira JD, Bertola L, Barroso L, Vieira M, Teixeira AL, Diniz BS. Oxidative DNA damage is increased in older adults with a major depressive episode: A preliminary study. Journal of Affective Disorders. 2021 Jan 15;279:106-10.
  33.  Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature. 2009 Oct 22;461(7267):1071-8.
  34.  Bernardini L, Barbosa E, Charão MF, Goethel G, Muller D, Bau C, Steffens NA, Santos Stein C, Moresco RN, Garcia SC, Souza Vencato M. Oxidative damage, inflammation, genotoxic effect, and global DNA methylation caused by inhalation of formaldehyde and the purpose of melatonin. Toxicology Research. 2020 Dec;9(6):778-89.
  35.  López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell. 2023 Jan 19;186(2):243-78.
  36. [36] Jorgensen A, Krogh J, Miskowiak K, Bolwig TG, Kessing LV, Fink-Jensen A, Nordentoft M, Henriksen T, Weimann A, Poulsen HE, Jorgensen MB. Systemic oxidatively generated DNA/RNA damage in clinical depression: associations to symptom severity and response to electroconvulsive therapy. Journal of affective disorders. 2013 Jul 1;149(1-3):355-62.
  37. Jorgensen A, Köhler-Forsberg K, Henriksen T, Weimann A, Brandslund I, Ellervik C, Poulsen HE, Knudsen GM, Frokjaer VG, Jorgensen MB. Systemic DNA and RNA damage from oxidation after serotonergic treatment of unipolar depression. Translational psychiatry. 2022 May 16;12(1):204.
  38. Munkholm K, Poulsen HE, Kessing LV, Vinberg M. Elevated levels of urinary markers of oxidatively generated DNA and RNA damage in bipolar disorder. Bipolar disorders. 2015 May;17(3):257-68.
  39.  Fanibunda SE, Deb S, Maniyadath B, Tiwari P, Ghai U, Gupta S, Figueiredo D, Weisstaub N, Gingrich JA, Vaidya AD, Kolthur-Seetharam U. Serotonin regulates mitochondrial biogenesis and function in rodent cortical neurons via the 5-HT2A receptor and SIRT1–PGC-1α axis. Proceedings of the National Academy of Sciences. 2019 May 28;116(22):11028-37.
  40.  Ruddell RG, Mann DA, Ramm GA. The function of serotonin within the liver. Journal of hepatology. 2008 Apr 1;48(4):666-75.
  41.  Jorgensen A, Broedbaek K, Fink-Jensen A, Knorr U, Soendergaard MG, Henriksen T, Weimann A, Jepsen P, Lykkesfeldt J, Poulsen HE, Jorgensen MB. Increased systemic oxidatively generated DNA and RNA damage in schizophrenia. Psychiatry Research. 2013 Oct 30;209(3):417-23.
  42.  Poulsen HE, Nadal LL, Broedbaek K, Nielsen PE, Weimann A. Detection and interpretation of 8-oxodG and 8-oxoGua in urine, plasma and cerebrospinal fluid. Biochimica et Biophysica Acta (BBA)-General Subjects. 2014 Feb 1;1840(2):801-8.
  43.  Jorgensen A, Krogh J, Miskowiak K, Bolwig TG, Kessing LV, Fink-Jensen A, Nordentoft M, Henriksen T, Weimann A, Poulsen HE, Jorgensen MB. Systemic oxidatively generated DNA/RNA damage in clinical depression: associations to symptom severity and response to electroconvulsive therapy. Journal of affective disorders. 2013 Jul 1;149(1-3):355-62.
  44.  Villa RF, Ferrari F, Gorini A, Brunello N, Tascedda F. Effect of desipramine and fluoxetine on energy metabolism of cerebral mitochondria. Neuroscience. 2016 Aug 25;330:326-34.
  45.  Herbet M, Szumełda I, Piątkowska-Chmiel I, Gawrońska-Grzywacz M, Dudka J. Beneficial effects of combined administration of fluoxetine and mitochondria-targeted antioxidant at in behavioural and molecular studies in mice model of depression. Behavioural Brain Research. 2021 May 7;405:113185.
Ahead of Print Subscription Original Research
Volume
Received 15/01/2025
Accepted 17/01/2025
Published 18/01/2025
146